The Liver Care Trial: screening for liver disease in individuals attending treatment for alcohol use disorder-study protocol for a randomized controlled study.
Pernille Dahlin, Peter Jepsen, Line Molzen...
https://pubmed.ncbi.nlm.nih.gov/41152905/Actively Recruiting
Led by Zealand University Hospital · Updated on 2023-05-17
408
Participants Needed
2
Research Sites
25 weeks
Total Duration
Researchers are evaluating the effectiveness of screening for liver disease using liver stiffness measurement in individuals undergoing treatment for alcohol use disorder who do not have a history of liver disease. This randomized controlled trial compares two approaches to screening, aiming to see if the intervention influences abstinence or light alcohol consumption after six months. Participants are randomly assigned to one of two groups the intervention group receives an invitation for a liver stiffness measurement using transient elastography, blood sampling, and a leaflet about alcohol-related disease the control group receives an invitation for blood sampling with Fib-4 screening only. The liver stiffness measurement is performed once, 1 to 2 weeks after randomization. During the study, participants will be monitored for alcohol consumption, with the primary outcome being abstinence or light consumption 10 or fewer units per week assessed six months after randomization. Secondary measures include the number of heavy drinking days and changes in alcohol use scores. The trial involves outpatient participants receiving alcohol use disorder treatment, and participation lasts at least six months following randomization.
CONDITIONS
The Liver Care Trial
P
Pernille Dahlin, MD
G
Gro Askgaard, PHD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Zealand University Hospital
Lead Sponsor
Novavi
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for screening and enrollment
Duration - 6 months since randomization
Participants undergo monitoring for liver disease through diagnostic testing and blood sampling based on group assignment.
1 to 2 visits depending on group assignment
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Pernille Dahlin, Peter Jepsen, Line Molzen...
https://pubmed.ncbi.nlm.nih.gov/41152905/Zealand University Hospital
Lead Sponsor
Novavi
Collaborating Sponsor